Articles 08.01.2022 Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients Business Wire Share Article
Cognito Shares HOPE Study Results at CTAD Business Wire 11.16.2026 Read More: Cognito Shares HOPE Study Results at CTAD
Cognito Expands Executive Leadership Team Business Wire 11.12.2026 Read More: Cognito Expands Executive Leadership Team
Rhode Island Life Science Hub and Cognito Therapeutics Launch Brain Health Collaboratory to Advance Innovation in Alzheimer’s Disease PR Newswire 10.13.2026 Read More: Rhode Island Life Science Hub and Cognito Therapeutics Launch Brain Health Collaboratory to Advance Innovation in Alzheimer’s Disease